Protocols
29 protocol(s) meet the specified criteria
Disease Site: Lymphoid Leukemia
Protocol No.TitleStatus
10-CBAA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indicationsOpen
A-TREATAmerican Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT) Open
A041501-CIRBA Phase III Trial To Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39) with Newly Diagnosed Precursor B-Cell ALLOpen
A051301 A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo In Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype Open
AALL05B1A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research SpecimensOpen
AALL08B1Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)Open
AALL0932Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)Open
AALL1131A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive MutationsOpen
AALL1231A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL)and T- Lymphoblastic Lymphoma (T-LLy)Open
AALL1331Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Open
AALL1621A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)Open
AALL1631International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.Open
ACCL1131A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)Open
ACCL1333A Phase III Randomized, Open Label, Multi-center Study on the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-AsparaginaseOpen
E1910A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults.Open
EBV-CTL-201Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Lymphomas and Lymphoproliferative Disorders in Immunocompromised Patients for Whom There are No Other Comparable OptionsOpen
INCB-18424-269A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic LeukemiaOpen
INCB-18424-365A Phase III Randomized Open-Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH 3)Open
LCCC0905Graft-Versus-Host Disease Solid Tissue ProcurementOpen
LCCC1241Complementary and Alternative medicine use at UNC clinicsOpen
LCCC1535Understanding Treatment Decision-making and Psychological Distress in Patients with Advanced CancerOpen
LCCC1541-ATLAdministration of autologous CAR-T cells targeting the CD19 antigen and containing the inducible caspase9 safety switch in patients with relapsed/refractory Acute Lymphoblastic Leukemia Open
LCCC1542Leukemia Specific Splice Isoforms as Neo-Antigens for T-cell Immunotherapy Open
LCCC1602Health services use and social outcomes of adult survivors of childhood cancerOpen
LCCC1637Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the treatment of Adult T-Cell Leukemia/Lymphoma: A Phase II Trial of the Rare Lymphoma Working GroupOpen
LCCC1726Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell TransplantationOpen
TGTX-LAB-001Screening Protocol to Determine High-risk Cytogenetic Features in Patients With Previously-treated CLL That May be Eligible for TG Therapeutics Trial UTX-IB-301Open (affiliates only)
UTX-IB-301A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL).Open (affiliates only)
UTX-TGR-304-REXA Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)Open (affiliates only)